DIAGNOSTIC VALUE OF DES-Gamma-CARBOXY PROTHROMBIN FOR RECURRENT HCC IN PATIENTS UNDERGOING PRECAUTIONARY SORAFENIB TREATMENT AFTER CURATIVE HEPATECTOMY

Jian Wang,Yue Yin,Ao Huang,Peiyao Fu,Xuxiao Chen,Xin Zhang,Jian Zhou
DOI: https://doi.org/10.19193/0393-6384_2020_2_165
2020-01-01
Acta medica mediterranea
Abstract:Objective: To investigate the diagnostic value of des-gamma-carboxy prothrombin (DCP) for recurrence in hepatocellular carcinoma (HCC) patients receiving precautionary sorafenib after curative liver resections. Methods: Eighty-five patients receiving curative hepatectomy and adjuvant sorafenib afterwards were enrolled. Their alpha-fetoprotein (AFP) and the DCP levels were dynamically followed up and were retrospectively analyzed. AFP and DCP levels were defined as positive when AFP levels > 20 ng/mL (AFP+) and DCP levels > 40 mAU/mL (DCP+), respectively. Results: At the cutoff point, 59 patients (69.4%) were confirmed with tumor recurrence. The recurrent group had significatuly higher DCP and AFP levels than the non-recurrent group (DCP: 45598.8 +/- 29317.1 mAU/mL vs 5538.6 +/- 1856.1 mAU/mL, P<0.0001; AFP: 10208.1 +/- 6079.5 ng/mL vs 3.8 +/- 2.2 ng/mL, P=0.0067). Both univariate and multivariate analysis showed DCP to be the independent risk factor for tumor recurrence. Moreover, DCP was more precise in diagnosing tumor relapse than AFP (AUC: 0.860 vs 0.669). In subgroups of patients with positive or negative preoperative AFP level, DCP was also superior to AFP (AUC in AFP+: 0.860 vs 0.772; AUC in AFP-: 0.887 vs 0.587, respectively) in diagnosing tumor relapse. At the same time, some dynamic change patterns of both DCP and AFP were discovered. Conclusion: Serum DCP is a reliable tumor marker of HCC recurrence with sorafenib as precautionary therapy after curative resections regardless of the preoperative AFP level.
What problem does this paper attempt to address?